Health Care/Hospital
ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed
MELBOURNE, Australia and INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in Part 2 (randomized treatment expansion) of its ProstACT Global Phase 3 study evaluating its lead prostate can...
2025-12-08 06:08
848
CARsgen's CAR-T Product Zevor-Cel Included in China's Commercial Health Insurance Innovative Drug Catalogue
SHANGHAI, Dec. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced today announced with great pleasure that its independently developed fully human BCMA-targeted CAR-T product, zevorcabtage...
2025-12-07 17:21
1513
All Approved Indications of Five Akeso's Innovative Drugs Included in China's Latest NRDL: Featuring Two First-in-Class Bispecifics with New First-Line Indications and Three Newly Negotiated Drugs
HONG KONG, Dec. 7, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the successful inclusion of all five of the Company's self-developed innovative drugs into the updated National Reimbursement Drug List (NRDL) for 2025, released byChina's National Healthcare Securi...
2025-12-07 14:18
1482
Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
SAN FRANCISCO and SUZHOU, China, Dec. 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
2025-12-07 11:40
1900
Leaders Dental Leads Korea's Prosthodontic Market With Large-Scale 300-Pyeong Production Infrastructure and a "Clinically Integrated Collaboration Model"
SEOUL, South Korea, Dec. 7, 2025 /PRNewswire/ -- Leaders Dental Laboratory, a major force driving the digitalization and large-scale transformation of Korea's dental laboratory industry, is solidifying its leadership with a production facility spanning over 300 pyeong. This extensive infrastructu...
2025-12-07 08:00
1582
Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting
SHANGHAI, Dec. 6, 2025 /PRNewswire/ -- Vivacta Bio, a spin-off company of Grit Biotherapeutics advancing in vivo CAR-T therapies for oncology and autoimmune diseases, today announced encouraging initial data from an investigator-initiated, first-in-human study of GT801, a T-LNP/mRNA–based in viv...
2025-12-06 22:45
1862
/C O R R E C T I O N -- Seegene Inc./
In the news release, "Seegene Establishes French Subsidiary to Expand European Footprint", issued05-Dec-2025 by Seegene Inc. over PR Newswire, we are advised by the company that the first sub-headline should read "France becomes Seegene's eighth overseas sales subsidiary and third inEurope, follo...
2025-12-06 00:00
2686
Neurophet Participates RSNA 2025, Showcased Real-World Clinical Use Cases of 'Neurophet AQUA AD'
* Demonstrated brain imaging analysis solutions, including 'Neurophet AQUA AD,' which enables monitoring of adverse effects associated with Alzheimer's disease treatments * Highlighted clinical cases that improved the safety of anti-amyloid therapy administration during an AI Theater session ...
2025-12-05 22:00
3229
Prof. Gang Shen's Research Paper about Mandibular Advancement Repositioning Technology in the Journal of Aligner Orthodontics
SHANGHAI, Dec. 5, 2025 /PRNewswire/ -- A clinical study developed by Professor Gang Shen's Orthodontic Team from Taikang Bybo Dental has been officially published in the Journal of Aligner Orthodontics (JAO). The article presents key findings on the use of Mandibular Advancement Repositioning The...
2025-12-05 18:00
1743
AbbVie-Sponsored Symposium at ESMO Asia 2025 Highlights Urgent Medical Need in Platinum-Resistant Advanced Ovarian Cancer
- Ovarian cancer remains an unmet medical need, and experts call for new strategies to define and treat platinum resistance in patients with advanced ovarian cancer[1],[2],[3] SINGAPORE, Dec. 5, 2025 /PRNewswire/ -- At an AbbVie-sponsored symposium at the ESMO Asia Congress 2025, experts g...
2025-12-05 16:00
961
Post-Disaster Support | Emergency Financial Assistance for Self-Financed Cancer Drugs
HONG KONG, Dec. 5, 2025 /PRNewswire/ -- The Level 5 fire at Wang Fuk House, Tai Po, on 26 November has left nearly 2,000 households homeless and plunged many families into hardship. Recovery and rebuilding after a disaster is a long journey that requires support from all sectors of society. To t...
2025-12-05 14:03
918
TransThera Publishes Clinical Studies of Tinengotinib (TT-00420) against Cholangiocarcinoma on Lancet
NANJING, China and GAITHERSBURG, Md., Dec. 4, 2025 /PRNewswire/ -- TransThera Sciences Inc. ("TransThera") announced the publication of clinical results from a US-based Phase 2 trial evaluating tinengotinib in patients with Cholangiocarcinoma (CCA) on The Lancet Gastroenterology and Hepatology (I...
2025-12-05 12:31
1663
ALL CONEC Selected for Dream Venture Star 11, Prize Award and MOU Scheduled on November 14
SEOUL, South Korea, Dec. 5, 2025 /PRNewswire/ -- ALL CONEC has been selected for the Dream Venture Star (DVS) 11 "Oracle × Uclick Program Business Meetup" support initiative. The official event will take place onNovember 14 at the Daejeon Center for Creative Economy and Innovation, where ALL CONE...
2025-12-05 11:00
1277
Agilent and Monash University Malaysia Mark 15-Year Partnership with New BioDiscovery Hub to Drive Regional Biotech Innovation
Collaboration aimed at accelerating R&D in both small- and large-molecule
analysis and building high-impact capabilities in fast-growing Asian markets
KUALA LUMPUR, Malaysia, Dec. 5, 2025 /PRNewswire/ -- Agilent Technologies Inc.
2025-12-05 09:30
1989
OTR Therapeutics Raises $100 Million in Series A Financing to Advance Early Innovation into Global Transformative Therapies
SHANGHAI, Dec. 4, 2025 /PRNewswire/ -- OTR Therapeutics, a biotechnology company dedicated to transforming early-stage innovations into globally impactful therapies, emerged from stealth and announced today the successful completion of a$100 million Series A financing closed in June 2025. The rou...
2025-12-05 09:00
1659
Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies
SAN FRANCISCO and SUZHOU, China, Dec. 4, 2025 /PRNewswire/ -- Innovent Biologics (HKEX: 01801) today announced that the global strategic collaboration with Takeda (TSE: 4502, NYSE: TAK) has closed and become effective following the satisfaction of all closing conditions. The collaboration, initia...
2025-12-05 07:38
1543
Renuka Iyer, MD, Named New Chief Medical Officer for National Comprehensive Cancer Network (NCCN)
Acclaimed oncologist from Roswell Park Comprehensive Cancer Center to help lead nonprofit responsible for gold standard guidelines that define and advance cancer care worldwide. PLYMOUTH MEETING, Pa., Dec. 4, 2025 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of ...
2025-12-04 21:04
1112
NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO
* Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread resistance * The Phase 1 ragistomig study achieved its objective, as the new Q6W extended dosing in...
2025-12-04 20:34
1228
Hope Medicine Inc.'s HMI-115 Received U.S. FDA Fast Track Designation, Accelerating Global Development
HMI-115 received FDA Fast Track Designation based on results from a Phase II clinical trial for endometriosis Mean dysmenorrhea pain score reduced by 42% Mean non-menstrual chronic pelvic pain score reduced by 52% Most patients maintained normal menstrual cycles No typical peri-menopausal sympt...
2025-12-04 20:08
1576
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics
Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), in global markets and China Collaboration designed to accelerate and expand the development of synergistic combinations with CR-001 and ADCs, including SKB105 CR...
2025-12-04 19:50
1398
Week's Top Stories
Most Reposted
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 278 media titles]
2025-12-26 12:55Vietnam's Newest EDM Destination, APLUS SAIGON, Debuts With Star-Studded Soft Opening Weekends Featuring Dombresky and Argy
[Picked up by 273 media titles]
2025-12-30 20:12
ACEN completes transition to 100% renewable energy
[Picked up by 273 media titles]
2025-12-29 18:53CYFIRMA's 2025 Impact Recap Showcases DeCYFIR, Preemptive External Threat Landscape Management Platform, Delivering Measurable Global Defense Against Emerging Threats
[Picked up by 263 media titles]
2025-12-29 09:00
ChinaAMC launches Depository Receipts of two Chinese flagship ETFs in Thai exchange
[Picked up by 259 media titles]
2025-12-29 14:27